(Q56582574)

English

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

scientific article 2011

In more languages

Statements

scholarly article

0 references

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy (English)

0 references

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

metastatic breast cancer

1 reference

based on heuristic

Igor N. Bondarenko

object named as

I. Bondarenko

2

0 references

object named as

R. Ward

8

0 references

author name string

M. Campone

1

0 references

S. Brincat

3

0 references

Y. Hotko

4

0 references

P. N. Munster

5

0 references

E. Chmielowska

6

0 references

P. Fumoleau

7

0 references

N. Bardy-Bouxin

9

0 references

E. Leip

10

0 references

K. Turnbull

11

0 references

C. Zacharchuk

12

0 references

R. J. Epstein

13

0 references

publication date

23 June 2011

0 references

Annals of Oncology

0 references

23

0 references

3

0 references

610-617

0 references

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

Src kinase activity is essential for osteoclast function

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR261

21 January 2018

Identifiers

10.1093/ANNONC/MDR261

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56582574&oldid=2111277305"